Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Harnessing the power of IFN for therapeutic approaches to COVID-19

Journal of Virology(2024)10.1128/jvi.01204-23Source: DataRank Database

Harnessing the power of IFN for therapeutic approaches to COVID-19 is a research paper published in Journal of Virology (2024). On theSindex it has a DataRank of 0.454. It has been cited 10 times, with 9 citing works in its 1-hop citation network.

N/A

0.454DataRank · unranked

Scored on demand from live citation data

Open Access10 citations · 9 citing works in its network

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 2.94)OA: greenTopics (37)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 79%Citation Network 21%

Base Score Contribution

0.360

From this paper's citation signal

Citation Network Contribution

0.0938

From 7 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 9 citers.

Peginterferon λ for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomized trial
Clinical Microbiology and Infection20251 citations28 referencesContributes 0.025
Advances in gut-lung axis research: clinical perspectives on pneumonia prevention and treatment
Frontiers in Immunology202527 citations185 referencesContributes 0.018
SARS-CoV-2 innate immune recognition and implications for respiratory health
Cytokine & Growth Factor Reviews202512 citations157 referencesContributes 0.016
Early mucosal IFN-α, IP-10, and IL-1RA and synchronized mucosal and systemic immune responses mediate COVID-19 disease progression
mBio20251 citations47 referencesContributes 0.015
Non-antiviral therapies for viral infections: Harnessing host mechanisms
International Immunopharmacology20254 citations127 referencesContributes 0.013

Authors (5)

Steven E. Bosinger ORCID,Daniel C. Douek ORCID,Gideon Schreiber ORCID,Mirko Paiardini ORCID,Elise G. Viox ORCID

Live enrichment

PubMed:38651899 PMC:PMC11092331 OpenAlex:https://openalex.org/W4395049348

HHS | National Institutes of Health

Grant: P510D011132-60S4

Emory University

Grant: Emory MP3 Grant

Fast Grants

Grant: Fast Grants #2144

NIH HHS

Grant: P51 OD011132

William I. H. and Lula E. Pitts Foundation (William I. H. & Lula E. Pitts Foundation)

William I. H. and Lula E. Pitts Foundation

William I. H. and Lula E. Pitts Foundation (William I. H. & Lula E. Pitts Foundation)

FWCI

2.94

Citation Percentile

0.9%

Citation Trend

2025

2026

greenLicense: https://doi.org/10.1128/ASMCopyrightv2

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11092331/pdf/jvi.01204-23.pdf

publisherhttps://journals.asm.org/doi/pdf/10.1128/jvi.01204-23

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11092331

journalhttps://doi.org/10.1128/jvi.01204-23

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesPhagocytosis and Immune RegulationAnimalsHumansAntiviral AgentsCOVID-19COVID-19 Drug TreatmentInterferonsSARS-CoV-2Virus Replication

MeSH Terms

COVID-19SARS-CoV-2COVID-19 Drug TreatmentAnimalsAntiviral AgentsHumansInterferonsVirus Replication

Keywords

BiologyCoronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BetacoronavirusComputational biologyPandemicPower (physics)OutbreakInfectious disease (medical specialty)Internal medicineDiseaseIFNIfn-iIfn-iiiCovid-19Sars-cov-2

Sustainable Development Goals

SDG 0: Good health and well-being